key: cord-0756457-7nellaxp
authors: Gelfand, J. M.; Armstrong, A. W.; Bell, S.; Anesi, G. L.; Blauvelt, A.; Calabrese, C.; Dommasch, E. D.; Feldman, S. R.; Gladman, D.; Kircik, L.; Lebwohl, M.; Lo Re, V.; Martin, G.; Merola, J. F.; Scher, J. U.; Schwartzman, S.; Treat, J. R.; Van Voorhees, A. S.; Ellebrecht, C. T.; Fenner, J.; Ocon, A.; Syed, M. N.; Weinstein, E. J.; Gondo, G.; Heydon, S.; Koons, S.; Ritchlin, C. T.
title: National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 2 – Advances in Psoriatic Disease Management, COVID-19 Vaccines, and COVID-19 Treatments
date: 2021-01-07
journal: J Am Acad Dermatol
DOI: 10.1016/j.jaad.2020.12.058
sha: 3094b4e667c0e98def52300f0ad225d72ef78045
doc_id: 756457
cord_uid: 7nellaxp

Objective To update guidance regarding the management of psoriatic disease during the COVID-19 pandemic. Study Design The task force (TF) includes 18 physician voting members with expertise in dermatology, rheumatology, epidemiology, infectious diseases, and critical care. The TF was supplemented by non-voting members, which included fellows and National Psoriasis Foundation (NPF) staff. Clinical questions relevant to the psoriatic disease community were informed by inquiries received by the NPF. A Delphi process was conducted. Results The TF updated evidence for the original 22 statements and added 5 new recommendations. The average of the votes was within the category of agreement for all statements, 13 with high consensus, 14 with moderate consensus. Limitations The evidence behind many guidance statements is variable in quality and/or quantity. Conclusion These statements provide guidance for the management of patients with psoriatic disease on topics ranging from how the disease and its treatments impact COVID-19 risk, how medical care can be optimized during the pandemic, what patients should do to lower their risk of getting infected with SARS-CoV-2 (including novel vaccination), and what they should do if they develop COVID-19. The guidance is a living document that is continuously updated by the TF as data emerge.

The COVID-19 pandemic has substantially worsened since the publication of version 1 of the NPF COVID-19 TF recommendations on September 4, 2020. 1 In just the ensuing 15 weeks alone there have been more than an additional 11,100,000 cases and 125,000 COVID-19 deaths in the US, and an additional nearly 50,000,000 cases and over 800,000 deaths worldwide 2 . Similar to the exponential growth of COVID-19 cases, basic biological and epidemiological knowledge related to this pandemic have expanded dramatically. In just a few months since our initial recommendations, there has been major advances in the understanding of how to prevent and treat COVID-19 as well as a substantial increase in data to inform management decisions for psoriatic disease patients during the pandemic. Therefore, this TF is providing updated scientifically-based guidance to promote optimal management of psoriatic disease during the pandemic.

J o u r n a l P r e -p r o o f METHODS The methods have been described in detail previously. 1 Briefly, the COVID-19 TF includes physicians, fellows, and senior NPF staff with a variety of expertise relevant to decision-making in the pandemic. The TF reviews COVID-19 literature weekly in relation to psoriatic disease and meets every 2-4 weeks to address 5 core questions related to the pandemic. Existing recommendations were updated based on evolving science, and approved by unanimous consent. New recommendations were generated using a modified Delphi process based on the RAND appropriateness method, including 2 rounds of voting with discussion in between (only one round was used for new recommendations that achieved high consensus on the first round). 3 Panel consensus was determined to be "low" when ≥5 votes fell into the 1-3 rating range with ≥5 votes concurrently falling into the 7-9 rating range. Consensus was interpreted as "high" if all 18 votes fell within a single tertile, with all other combinations considered as "moderate" levels of consensus. The results were analyzed by the NPF with an independent analysis of the data by a non-voting member of the TF.

J o u r n a l P r e -p r o o f

The TF reaffirms the initial 22 guidance statements with updated data, and has issued 5 new recommendations. The median was within the category of agreement for all new statements, with the number of votes outside the range of agreement being only 2 for the one new statement where agreement was not unanimous. All guidance statements were recommended, 13 with high consensus, and the 14 with moderate consensus. Psoriasis patients are more prone to thrombosis and comorbidities that portend worse outcomes and may be more susceptible to infection, which raised concerns that they could be at increased risk for SARS-CoV-2 infection and worse COVID-19 outcomes. [4] [5] [6] [7] [8] Nevertheless, patients with psoriatic disease appear to have similar rates of infection with SARS-CoV-2 and COVID-19 outcomes as the general population with multiple new studies from Italy, which primarily focused on patients with psoriasis receiving oral or biologic treatment, supporting our initial recommendation (1.1). [9] [10] [11] Additional new studies of psoriatic arthritis (PsA) patients nested within cohorts of rheumatic disease patients also suggest that they have similar rates of infection with SARS-CoV-2 and COVID-19 outcomes as the general population. [12] [13] [14] However, the risk of COVID-19 in autoimmune diseases was higher than in control patients (OR: 2.19, 95% CI: 1.05 to 4.58) in a meta-analysis of seven casecontrolled studies. 15 The severity of COVID-19 continues to be primarily driven by risk factors such as current smoking, male sex, older age and underlying comorbidities (Guidance 1.2). [16] [17] [18] [19] New data confirm that age, J o u r n a l P r e -p r o o f male sex, and pre-existing comorbidities are also important drivers of poor COVID- 19 Similarly, use of immunosuppressive/immunomodulating therapy was not associated with an increased risk for COVID-19 in a cohort of 5,302 patients with inflammatory bowel disease (IBD). 25 This finding was supported by the SECURE-IBD registry that demonstrated no increase in severe outcomes in patients on TNFi or anti-IL12/23 monotherapy. 26 Patients with rheumatic disease do not appear to be at higher risk of contracting SARS-CoV-2 infection or of developing severe COVID-19 when on anti-TNF therapy. 15, 27, 28 Nevertheless, uncertainty remains based on the quality of the existing data and lack of detailed analysis of patients at high risk due to age and/or comorbidity; therefore, shared decision-making between clinician and patient is recommended (Guidance 2. PsA as assessed by patient-reported outcomes. 30 Nevertheless, reductions in in-person care during the pandemic may be associated with a delay in diagnosis and treatment of malignancies, including melanoma. 31, 32 Universal masking for staff, clinicians and patients, restrictions on visitation, and liberal RT-PCR testing of symptomatic and asymptomatic patients are very effective in limiting SARS-CoV-2 spread, with nosocomial transmission exceptionally rare. 33, 34 Therefore, patients should be informed that inperson medical care, including phototherapy (3.3), can be delivered safely with minimal risk of COVID-19 transmission in the clinical setting when safeguards are maintained. 35, 36 Outbreaks in the clinical setting that have occurred have been due to lack of masking in patient care areas and a lack of distancing among staff while eating unmasked. 33 J o u r n a l P r e -p r o o f methods to prevent COVID-19 were lowest among adults aged 18-29 years (73%) and highest among those aged >60 years (86%). 38 An international survey of psoriasis patients found that rates of COVID-19 prevention measures were slightly higher in those receiving biologics for psoriasis than in those receiving nonbiologic systemic therapies. 20 Since our first recommendations, the major advance in protection from COVID-19 is the advent of highly effective vaccines using mRNA technology, which results in temporary expression of the SARS-CoV-2 spike protein in human cells after injection, triggering an immune response ( Table 2 ).

The two-dose, 21-day-apart, regimen of BNT162b2 (manufactured by Pfizer and BioNTech) conferred 95% protection against COVID-19, with an excellent safety profile similar to that of other viral vaccines, and was granted Emergency Use Authorization (EUA) on December 11, 2020 by the US Food and Drug Administration (FDA). 39, 40 Similarly, the two-dose, 28-day-apart, regimen of mRNA-1273 (manufactured by Moderna) conferred 94.5% protection against COVID-19 (FDA EUA pending). 41 Therefore, the TF recommends that patients with psoriatic disease, who do not have contraindications to vaccination, should receive a mRNA-based COVID-19 vaccine as soon as it becomes available to them (4.5). Additional vaccine platforms are undergoing testing (Table 2) . 42 The effect of psoriasis treatment on the efficacy of COVID-19 vaccines is unknown. Based on a review of the literature, methotrexate treatment with doses commonly used in psoriatic disease patients lowers the humoral response to seasonal influenza and pneumococcal vaccines, and temporary discontinuation of methotrexate for 2 weeks after influenza immunization improves the immunogenicity of seasonal influenza vaccine. 43 CoV-2, are recommended (5.2). [54] [55] [56] [57] [58] For hospitalized patients meeting specific criteria, in addition to remdesivir and dexamethasone, baricitinib in combination with remdesivir is an option as it reduces recovery time and new infections in hospitalized COVID-19 patients compared to remdesivir alone. 59 However, baricitinib had no mortality benefit, can be prothrombotic, and is recommended only when corticosteroids cannot be used. 59, 60 Furthermore, remdesivir efficacy is modest, and international trials did not find mortality benefit. 61, 62 Additional evidence suggests hydroxychloroquine is not effective for the prevention or treatment of COVID-19; therefore, the TF emphasizes that its use be restricted to clinical trials (5.4.1). [63] [64] [65] [66] [67] The evidence that convalescent plasma is effective for COVID-19 is limited despite the FDA EUA; therefore, the TF recommends that it be used primarily in clinical trials (5.4.2). 68, 69 Ivermectin, has in vitro activity against SARS-CoV-2; however, doses up to 100-times higher than those approved for use in humans would be required to achieve antiviral effects against COVID-19, raising safety concerns even if therapeutic levels could feasibly be achieved. [70] [71] [72] [73] Therefore, the TF recommends ivermectin only be used in the setting of a clinical trial (5.4.3) .

Based on limited available data, and to be consistent with prescribing information, it may be prudent to hold treatments that target the immune system in the setting of suspected or confirmed SARS-CoV-2 infection, but the ultimate decision should be made on a case-by-case. Patients with psoriatic disease should be aware that infection with SARS-CoV-2 may result in a flare of psoriasis, including pustular flares (5.6) . [74] [75] [76] [77] [78] [79] [80] [81] J o u r n a l P r e -p r o o f Patients with psoriatic disease who become infected with SARS-CoV-2 should follow CDC guidance on home isolation and discuss with their healthcare providers when they can end home isolation (5.7, Version 1 E- Table 9 ). 1, [82] [83] [84] In the event someone with psoriatic disease has close contact (Version 1 E- Table 10 ) with an individual with suspected or confirmed SARS-CoV-2 infection, they should follow their local public health authority guidance for the recommended duration of quarantine. 1 CDC recommends a quarantine period of 14 days after last contact with a person who has COVID-19, assuming one remains asymptomatic, but offers an option to shorten quarantine to end after Day 10 from last contact, or Day 7 with appropriately timed diagnostic testing (Guidance 5.8). 85 Individuals who have had COVID-19 within the past 3 months do not need to quarantine following close contact with someone who is infected, as long as they do not develop symptoms again. 86 The decision regarding continuing or holding psoriasis treatments during a period of quarantine should be individualized on a case-by-case basis between patient and provider.

Resumption of psoriasis and/or PsA treatments held during SARS-CoV-2 infection should be decided on a case-by-case basis (5.5). The persistence of one or more symptoms of COVID-19, such as fatigue or joint pain, beyond the acute phase of the illness can occur, 87 and may complicate the decision to re-start psoriasis or PsA medications. Therefore, shared decision-making between the patient and their provider(s) is recommended (2.5). population-based studies of patients with psoriatic disease (particularly those with increased COVID-19 risk due to age and/or comorbidity), with appropriate comparator groups, adjustment for relevant confounding variables, and complete ascertainment of clinically important COVID-19 outcomes are urgently needed. 89 Second, the guidance is neither intended to be proscriptive nor comprehensive.

The ultimate judgment regarding how these recommendations should be followed is best left with the treating clinician and the patient in light of the circumstances presented by the individual patient, and the variability and biological behavior of the disease and therapeutics.

The recommendations are a "living" document that will be updated and amended when necessary by the rapidly evolving science of COVID-19. Readers are encouraged to visit https://www.psoriasis.org/covid-19-resource-center regularly for the latest guidance from the TF in order to promote optimal care and outcomes for patients with psoriatic disease during the pandemic. 

The likelihood of poor outcomes from COVID-19 is driven by risk factors such as older age and comorbidities such as chronic heart, lung, or kidney disease and metabolic disorders such as diabetes and obesity. Patients with psoriatic disease are more prone to these comorbidities, particularly in those with more severe disease.

It is not known with certainty if treatments for psoriasis and/or psoriatic arthritis meaningfully alter the risks of contracting SARS-CoV-2 (the virus that causes COVID-19 illness) or having a worse course of COVID-19 illness. Existing data generally suggest that treatments for psoriasis and/or psoriatic arthritis do not meaningfully alter the risk of acquiring SARS-CoV-2 infection or having worse COVID-19 outcomes.

It is recommended that patients who are not infected with SARS-CoV-2 continue their biologic or oral therapies for psoriasis and/or psoriatic arthritis in most cases. Shared decision-making between clinician and patient is recommended to guide discussions about use of systemic therapies during the pandemic (see guidance 2.5 for definition of shared decision making).

Chronic systemic corticosteroids should be avoided if possible for the management of psoriatic arthritis. If patients require chronic systemic corticosteroids for management of psoriatic arthritis, the dose should be tapered to the lowest dose necessary to achieve the desired therapeutic effect. Chronic systemic corticosteroid use for the treatment of psoriatic disease at the time of acute infection with SARS-CoV-2 may be associated with worse outcomes from COVID-19 illness. It is important to note, however, that corticosteroids may improve outcomes for COVID-19 when initiated in hospitalized patients requiring oxygen treatment.

Individuals newly diagnosed with psoriasis and/or psoriatic arthritis or who are currently not receiving treatment should be aware that untreated psoriatic disease is associated with serious impact on physical and emotional health, and in the case of psoriatic arthritis, can lead to permanent joint damage and disability. Shared decisionmaking between clinician and patient is recommended to guide discussions about use of systemic therapies during the pandemic (see guidance 2.5 for shared decision making).

Providers recommend shared decision-making with patients. Shared decision-making between clinician and patient should be guided by several factors, including the potential benefits of treatment, the activity of skin and/or joint disease and response to previous therapies, as well as the patient's underlying risk for poor COVID19 Moderate J o u r n a l P r e -p r o o f outcomes, and ability to maintain measures to prevent infection with SARS-CoV-2 such as hand hygiene, wearing of masks, and physical distancing as required by pandemic conditions. A review of known benefits of treatment accompanied by acknowledgment of the uncertainty related to the COVID-19 pandemic and a discussion of a patient's individual circumstances and preferences should guide decision-making.

Telemedicine should be offered to manage patients wherever possible when local restrictions or pandemic conditions limit the ability for in-person visits. The following patients can be managed with telemedicine: Patients who are clinically stable and previously started on psoriatic disease treatment. Patients requiring a follow-up visit and refills for medication. New patients without timely access to in-person visits.

Patients diagnosed with COVID-19 who are experiencing a significant flare. If telemedicine visits become inadequate to monitor patients' disease progress or manage new or evolving symptoms or signs of skin and joint disease, clinicians and patients should consider in-person visits.

The following patients should be considered for in-person care if pandemic conditions allow (i.e., the clinical practice is open to see patients in person) and Standard Operating Procedures are observed (i.e. social distancing, hand washing and masking). Patients at risk for melanoma and non-melanoma skin cancer should be seen in person at a frequency consistent with standard of care for a full skin examination. New patients establishing care. Patients experiencing unstable psoriatic disease/flares. Patients requiring a thorough skin/or joint examination and a full physical examination for rheumatology patients.

Providers recommend the recent guidelines published by Lim et al 35 . on how to optimize safety of office phototherapy for the patients and staff in the setting of the pandemic. See Table 5 for details.

Patients should be advised to follow measures that prevent infection with SARS-CoV-2. These preventative measures include: To practice good hand hygiene, to maintain physical distancing from non-household members, and to wear a face covering of the nose and mouth when indoors (except in their own home), and when outdoors, but unable to maintain physical distancing. Face coverings should not be used in children under 2 years old due to risk of suffocation. See E Table 6 for details.

Patients with psoriatic disease should follow measures to prevent infection with SARS-CoV-2 in the workplace. If the work place environment does not allow for maintenance of prevention measures, a shared decision-making process between the patient and his/her clinician is recommended to determine if specific accommodations are medically necessary, especially for individuals whom, due to age or underlying health conditions, are at especially high risk for poor COVID19 outcomes.

Youth with psoriatic disease should follow measures to prevent infection with SARS-CoV-2 while at school. These measures include maintaining 6 feet of physical distancing, consistently wearing masks if over the age of 2 years, and washing hands frequently. If the school environment is unable to ensure these prevention measures or families believe their child may not be able to adhere to these practices, we encourage discussion with the patient, caregivers, and his/her clinician to collectively develop a learning plan in the best interest and safety of the child.

J o u r n a l P r e -p r o o f

Patients with psoriatic disease should receive the seasonal inactivated (e.g. killed) influenza vaccine. While this vaccine will not protect against SARS-CoV-2, influenza vaccine lowers the risk of infection from seasonal influenza, which is of special importance to individual and public health during the COVID-19 pandemic. Patients taking systemic medications for psoriasis or psoriatic arthritis should discuss the timing of influenza vaccination with respect to their systemic psoriatic medications with their health care provider in order to optimize the response to the influenza vaccine.

Patients with psoriatic disease, who do not have contraindications to vaccination, should receive an mRNA-based COVID-19 vaccine as soon as it becomes available to them based on federal, state, and local guidance. Systemic medications for psoriasis or psoriatic arthritis are not a contraindication to the mRNA-based COVID-19 vaccine. If vaccine supply is limited, the TF recommends following CDC's prioritization guidelines for early vaccination for selected groups based on their comorbidities and work setting.

https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations-process.html High

It is recommended that patients who are to receive a mRNA-based COVID-19 vaccine continue their biologic or oral therapies for psoriasis and/or psoriatic arthritis in most cases. Shared decision-making between clinician and patient is recommended to guide discussions about use of systemic therapies during the pandemic (see guidance 2.5 for definition of shared decision making).

For patients with psoriatic disease deciding whether or not to participate in a COVID-19 therapeutic or vaccine clinical trial, the TF recommends that the decision should be made on a case-by-case basis with shared decision-making between the patient, researcher, and provider.

Patients with psoriatic disease who become infected with SARS-CoV-2 should monitor their symptoms and discuss the management of their treatments with their health care providers.

Patients with psoriatic disease who become infected with SARS-CoV-2 should be prescribed and adhere to evidence-based COVID-19 therapies. Evidence-based therapies* currently include supportive care for all patients and: For outpatients:

• Bamlanivimab for patients meeting specific criteria and who are at high risk for progressing to severe COVID-19 and/or hospitalization • Casirivimab and imdevimab to be administered together for patients meeting specific criteria and who are at high risk for progressing to severe COVID-19 and/or hospitalization For hospitalized patients:

• Dexamethasone (systemic steroids) for patients meeting specific criteria • Remdesivir treatment for patients meeting specific criteria • Baricitinib, in combination with remdesivir, for patients meeting specific criteria The care of the hospitalized patient should include consultation with rheumatologists, dermatologists, and/or infectious disease specialists as medically necessary.

*Evidence based therapies are those that have been tested in well-conducted randomized controlled clinical trials, and have proven benefit on clinically relevant Moderate J o u r n a l P r e -p r o o f COVID19 outcomes.

Systemic corticosteroids for the management of COVID-19 in patients with psoriatic disease are not contraindicated and should not be withheld due to the concern of potentially flaring psoriasis upon withdrawal of corticosteroids when evidence demonstrates the effectiveness for treating COVID-19 illness.

Hydroxychloroquine or chloroquine are not recommended for the prevention or treatment of COVID-19 in patients with psoriatic disease outside of a clinical trial.

Cases of psoriasis flare have been reported in patients on anti-malarial medications, but the clinical significance is not well understood.

High

At this time, due to insufficient data to recommend for or against the use of convalescent plasma for the treatment of COVID-19 in patients with psoriatic disease, the TF recommends convalescent plasma to primarily be used in the setting of a clinical trial. Outside of a clinical trial, its use may be considered on a case-by-case basis with shared decision-making between the patient and provider.

Ivermectin is not recommended for the prevention or treatment of COVID-19 in patients with psoriatic disease outside of a clinical trial.

Resumption of psoriasis and/or psoriatic arthritis treatments held during SARS-CoV-2 infection should be decided on a case-by-case basis. Most patients can restart psoriasis and/or psoriatic arthritis treatments after complete resolution of COVID-19 symptoms. In those who have had a severe hospital course, shared decision making made on a case-by-case basis is recommended.

Patients with psoriatic disease should be aware that infection with SARS-CoV-2 may result in a flare of psoriasis based on case reports. The clinical significance of the risk of COVID-19 flaring psoriasis is not known.

Patients with psoriatic disease who become infected with SARS-CoV-2 should follow CDC guidance on home isolation and discuss with their healthcare providers when they can end home isolation. We recommend waiting a minimum of 10 days after COVID-19 symptom onset, along with fever resolution for 24 hours without antipyretics and improvement in other symptoms, before ending home isolation and returning to work, as patients are unlikely to be infectious after this point. In patients with severe cases of COVID-19 or when psoriasis patients are on medications with immunosuppressive effects, we recommend a case-by-case approach to determining the length of home isolation.

Patients with close contact to someone with SARS-CoV-2 infection should quarantine themselves for 14 days after the last contact and discuss the management of their psoriatic disease treatment with their medical provider(s).

J o u r n a l P r e -p r o o f 

Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1

COVID-19 Map -Johns Hopkins Coronavirus Resource Center: @JohnsHopkins

The RAND/UCLA appropriateness method user's manual

Psoriasis severity and the prevalence of major medical comorbidity: a population-based study

Risk of Serious Infection, Opportunistic Infection, and Herpes Zoster among Patients with Psoriasis in the United Kingdom

The risk of stroke in patients with psoriasis

Risk of venous thromboembolism in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a general population-based cohort study

Activated Platelets Induce Endothelial Cell Inflammatory Response in Psoriasis via COX-1

The Risk of COVID-19 Pandemic in Patients with Moderate to Severe Plaque Psoriasis Receiving Systemic Treatments. Vaccines (Basel) 2020

Characteristic of Chronic Plaque Psoriasis Patients Treated with Biologics in Italy during the COVID-19 Pandemic: Risk Analysis from the PSO-BIO-COVID Observational Study

Incidence rates of hospitalization and death from COVID-19 in patients with psoriasis receiving biological treatment: A Northern Italy experience

COVID-19 in French patients with chronic inflammatory rheumatic diseases: clinical features, risk factors and treatment adherence

Coronavirus disease 2019 (COVID-19) in autoimmune and inflammatory conditions: clinical characteristics of poor outcomes

Clinical course, severity and mortality in a cohort of patients with COVID-19 with rheumatic diseases

Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis

Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission

Comorbidities and the risk of severe or fatal outcomes associated with coronavirus disease 2019: A systematic review and meta-analysis

Rapid Epidemiological Analysis of Comorbidities and Treatments as risk factors for COVID-19 in Scotland (REACT-SCOT): A population-based case-control study

Severity and Mortality associated with COPD and Smoking in patients with COVID-19: A Rapid Systematic Review and Meta-Analysis

Factors associated with adverse COVID-19 outcomes in patients with psoriasis—insights from a global registry–based study

Characteristic of Chronic Plaque Psoriasis Patients Treated with Biologics in Italy during the COVID-19 Pandemic: Risk Analysis from the PSO-BIO-COVID Observational Study

Does therapy with biological drugs influence COVID-19 infection? Observational monocentric prevalence study on the clinical and epidemiological data of psoriatic patients treated with biological drugs or with topical drugs alone

Incidence of severe COVID-19 outcomes in psoriatic patients treated with systemic therapies during the pandemic: a Biobadaderm cohort analysis

Clinical outcomes of COVID-19 in patients taking tumor necrosis factor inhibitors or methotrexate: A multicenter research network study

Immunosuppressive Therapy and Risk of COVID-19 Infection in Patients With Inflammatory Bowel Diseases

Effect of IBD medications on COVID-19 outcomes: results from an international registry

Antecedent immunosuppressive therapy for immune-mediated inflammatory diseases in the setting of a COVID-19 outbreak

Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic diseasemodifying anti-rheumatic drugs

Impact of Corticosteroids in Coronavirus Disease 2019 Outcomes: Systematic Review and Meta-analysis

Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort

Impact of COVID-19 on Cancer Care: How the Pandemic Is Delaying Cancer Diagnosis and Treatment for American Seniors

Delayed melanoma diagnosis in the COVID-19 era: increased breslow thickness in primary melanomas seen after the COVID-19 lockdown

Hospital-Acquired SARS-CoV-2 Infection: Lessons for Public Health

Incidence of Nosocomial COVID-19 in Patients Hospitalized at a Large US Academic Medical Center

Recommendations for phototherapy during the COVID-19 pandemic

Clinical Research after COVID-19: Embracing a New Normal

COVID-19 Mitigation Behaviors by Age Group -United States

Emergency Use Authorization (EUA) for emergency use of Pfizer-BioNTech COVID-19 Vaccine2020

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

FDA briefing document Moderna COVID-19 Vaccine

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil

Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial

A Systematic Review and Metaanalysis of Antirheumatic Drugs and Vaccine Immunogenicity in Rheumatoid Arthritis

Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: a prospective study

Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab

T-cell-mediated immune response to pneumococcal conjugate vaccine (PCV-13) and tetanus toxoid vaccine in patients with moderate-to-severe psoriasis during tofacitinib treatment

The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis

Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept

High Immunogenicity to Influenza Vaccination in Crohn's Disease Patients Treated with Ustekinumab

Immunogenicity and safety of vaccination against seasonal influenza vaccine in patients with psoriatic arthritis treated with secukinumab

Secukinumab does not impair the immunogenic response to the influenza vaccine in patients

Response to Tetanus and Pneumococcal Vaccination Following Administration of Ixekizumab in Healthy Participants

An EUA for Bamlanivimab-A Monoclonal Antibody for COVID-19

Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19

Prepare for the Future: Dissecting the Spike to Seek Broadly Neutralizing Antibodies and Universal Vaccine for Pandemic Coronaviruses

Statement on REGN-COV2 emergency use authorization request2020

REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19

The COVID-19 Treatment Guidelines Panel's Statement on the Emergency Use Authorization of Baricitinib for the Treatment of COVID-192020

Remdesivir for the Treatment of Covid-19 -Final Report

Covid-19: Remdesivir has little or no impact on survival, WHO trial shows

Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection

A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19

Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19

Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19

Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19

Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)

A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia

The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro

COVID-19 and the rush for self-medication and self-dosing with ivermectin: A word of caution

Food & Drug Administration. FAQ: COVID-19 and ivermectin intended for animals2020

Deaths associated with ivermectin treatment of scabies

A case of severe psoriatic erythroderma with COVID-19

A case of exacerbation of psoriasis after oseltamivir and hydroxychloroquine in a patient with COVID-19: Will cases of psoriasis increase after COVID-19 pandemic?

Covid-19 and exacerbation of psoriasis

Guttate psoriasis secondary to COVID-19

Hydroxychloroquine effects on psoriasis: A systematic review and a cautionary note for COVID-19 treatment

Pustular psoriasis exacerbated by COVID-19 in a patient with the history of psoriasis

Generalized pustular psoriasis following COVID-19

New-onset pustular psoriasis in the setting of severe acute respiratory syndrome coronavirus 2 infection causing coronavirus disease 2019

Discontinuation of isolation for persons with COVID-19 not in healthcare settings

Shedding of infectious virus in hospitalized patients with coronavirus disease-2019 (COVID-19): duration and key determinants

Universal Masking to Prevent SARS-CoV-2 Transmission-The Time Is Now

Options to reduce quarantine for contacts of persons with sars-cov-2 infection using symptom monitoring and diagnostic testing2020

Persistent Symptoms in Patients After Acute COVID-19

GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables